16 Oct 16

Orfan Biotech is a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria. Orfan has a collaboration with o2h discovery involving financial and medicinal chemistry support.


Hans Maag, Med Chemist, Orfan,

“We are very thankful to the research partnership with o2h discovery which is allowing Orfan to efficiently and effectively drive our Medicinal Chemistry programs. This partnership demonstrates the power of bringing together insights generated by the Orfan founders with state-of-the art drug discovery and chemistry expertise built in collaboration with the o2h discovery”

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative